Literature DB >> 20691813

The role of adenosine receptors in rheumatoid arthritis.

Katia Varani1, Melissa Padovan, Marcello Govoni, Fabrizio Vincenzi, Francesco Trotta, Pier Andrea Borea.   

Abstract

Rheumatoid arthritis (RA), is the most common inflammatory musculoskeletal disease inducing diminished quality-of-life in the affected individuals and having major impact on society due to decrease work ability. Early diagnosis and immediate, effective therapy are crucial in order to prevent unfavorable outcome. Treatment of RA has progressed during the past two decades thanks to the advent of a large number of new agents targeting different specific molecules and pathways involved in the modulation of the inflammation. In this scenario an important role is covered by adenosine, a purine nucleoside released from a variety of cells in response to metabolic and inflammatory stress, which is considered to be a potent endogenous regulator acting through its interaction with 4 cell surface receptors named as A(1), A(2A), A(2B) and A(3). Adenosine receptor stimulation has complex effects on the release of pro-inflammatory cytokines depending on selective receptor engagement. Recent data show the involvement of adenosine pathways in RA and its potential therapeutic implications.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20691813     DOI: 10.1016/j.autrev.2010.07.019

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  14 in total

Review 1.  Purinergic signalling in the musculoskeletal system.

Authors:  Geoffrey Burnstock; Timothy R Arnett; Isabel R Orriss
Journal:  Purinergic Signal       Date:  2013-08-14       Impact factor: 3.765

Review 2.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 3.  Regulation of mast cell responses in health and disease.

Authors:  Alasdair M Gilfillan; Michael A Beaven
Journal:  Crit Rev Immunol       Date:  2011       Impact factor: 2.214

Review 4.  Adenosine kinase: exploitation for therapeutic gain.

Authors:  Detlev Boison
Journal:  Pharmacol Rev       Date:  2013-04-16       Impact factor: 25.468

5.  A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release.

Authors:  Katia Varani; Melissa Padovan; Fabrizio Vincenzi; Martina Targa; Francesco Trotta; Marcello Govoni; Pier Andrea Borea
Journal:  Arthritis Res Ther       Date:  2011-12-06       Impact factor: 5.156

6.  The anti-tumor effect of A3 adenosine receptors is potentiated by pulsed electromagnetic fields in cultured neural cancer cells.

Authors:  Fabrizio Vincenzi; Martina Targa; Carmen Corciulo; Stefania Gessi; Stefania Merighi; Stefania Setti; Ruggero Cadossi; Pier Andrea Borea; Katia Varani
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

7.  Multi-omic landscape of rheumatoid arthritis: re-evaluation of drug adverse effects.

Authors:  Paolo Tieri; XiaoYuan Zhou; Lisha Zhu; Christine Nardini
Journal:  Front Cell Dev Biol       Date:  2014-11-04

Review 8.  Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension.

Authors:  Allan K N Alencar; Guilherme C Montes; Eliezer J Barreiro; Roberto T Sudo; Gisele Zapata-Sudo
Journal:  Front Pharmacol       Date:  2017-12-04       Impact factor: 5.810

Review 9.  Unfolding Role of a Danger Molecule Adenosine Signaling in Modulation of Microbial Infection and Host Cell Response.

Authors:  Jaden S Lee; Özlem Yilmaz
Journal:  Int J Mol Sci       Date:  2018-01-09       Impact factor: 5.923

10.  A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats.

Authors:  Fabrizio Vincenzi; Melissa Padovan; Martina Targa; Carmen Corciulo; Sarah Giacuzzo; Stefania Merighi; Stefania Gessi; Marcello Govoni; Pier Andrea Borea; Katia Varani
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.